GlassScriptPhysician profile
Todd T Nguyen
NPI 1548249030
$14,509.02
in general payments reported to CMS, 2019-2025
78 companies · $2,105 in 2025
The $2,105 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,714 · 2020: $1,917 · 2021: $2,754 · 2022: $2,435 · 2023: $1,759 · 2024: $1,825 · 2025: $2,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,560 · Education: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,559.91 |
| Education | $128.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,031.25 | 2019-2025 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $1,001.52 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Abbvie INC. | $855.56 | 2019-2025 | |
| Welch Allyn | $850.50 | 2021 | |
| Novo Nordisk INC | $713.79 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $646.39 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Baxter Healthcare | $625.06 | 2022 | |
| Pfizer INC. | $619.57 | 2019-2025 | |
| Amgen INC. | $578.14 | 2019-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $467.39 | 2019-2025 | Xifaxan, Trulance |
| Collegium Pharmaceutical, INC. | $448.21 | 2019-2025 | Belbuca |
| Abbott Laboratories | $432.70 | 2019-2025 | Freestyle Libre 3, Ionicrf, Proclaim |
| Astellas Pharma US INC | $427.23 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $349.63 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.33 | 2019-2025 | Jardiance, Spiriva Respimat |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.